Biomolecules & Therapeutics 2023; 31(6): 655-660
Stimulatory Anticancer Effect of Resveratrol Mediated by G Protein-Coupled Estrogen Receptor in Colorectal Cancer
Nayun Kim1,2, Junhye Kwon3, Ui Sup Shin4 and Joohee Jung1,2,*
1College of Pharmacy, Duksung Women’s University, Seoul 01369,
2Duksung Innovative Drug Center, Duksung Women’s University, Seoul 01369,
3Department of Radiological & Clinical Research, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul 01812,
4Department of Surgery, Korea Cancer Center Hospital, KIRAMS, Seoul 01812, Republic of Korea
Tel: +82-2-901-8731, Fax: +82-2-901-8386
Received: March 30, 2023; Revised: May 20, 2023; Accepted: May 23, 2023; Published online: October 11, 2023.
© The Korean Society of Applied Pharmacology. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Colorectal cancer (CRC) is one of the most high-risk cancers; however, it has been suggested that estrogen signaling in CRC could have a protective effect. Therefore, we focused on the function of the G protein-coupled estrogen receptor (GPER) among the estrogen receptors in CRC. In this study, we investigated the therapeutic effect of resveratrol via GPER in CRC (RKO and WiDr) cells, CRC cell-derived xenograft models, and organoids (30T and 33T). Resveratrol significantly suppressed cell viability and proliferation in highly GPER-expressing RKO cells compared to that in low GPER-expressing WiDr cells. In xenograft models, resveratrol also delayed tumor growth and exhibited a high survival rate depending on GPER expression in RKO-derived tumors. Furthermore, resveratrol significantly inhibited the viability of organoids with high GPER expression. Additionally, the anticancer effect of resveratrol on CRC showed that resveratrol rapidly responded to GPER, while increasing the expression of p-ERK and Bax and cleaving PARP proteins.
Keywords: Anticancer, Colorectal cancer, Organoid, Xenograft model, Resveratrol, G protein-coupled estrogen receptor

Colorectal cancer (CRC) is one of the most representative high-risk cancers, ranking third in terms of cancer incidence and second in terms of mortality, according to 2020 GLOBOCAN statistics (Sung et al., 2021). CRC risk factors vary by country according to age and gender, with males showing higher incidence and mortality rates than females (Khil et al., 2021). Hormones can be considered as the primary factor contributing to gender sensitivity, and several previous studies have revealed the protective effect of estrogen against CRC (Di Leo et al., 2001).

Therefore, this study focused on the G protein-coupled estrogen receptor (GPER), which has previously been identified as an additional receptor for estrogen. GPER is one of the seven transmembrane receptors and acts as a mediator of estrogen in the nervous, immune, cardiovascular, and reproductive systems, as well as in bone metabolism and cancer. Considering that GPERs are not located inside the nucleus like typical estrogen receptors (ERs), such as ERα and ERβ, but are rather located within the cell membrane, they have different mechanisms of action, which have not yet been fully clarified (Liu et al., 2017; Jung, 2019; Luo and Liu, 2020).

To understand the action of GPER, several ligands including estrogen have been investigated (Qiu et al., 2021). G1 Tomoxifen, as a selective ER modulator, and ICI 182,780, as an ER antagonist, are known as GPER agonists, while G15 is known as a GPER antagonist (Hsu et al., 2019). Various flavonoids known as phytoestrogen are also considered to act via GPER (D’Arrigo et al., 2021). Resveratrol (3,5,4′-trihydroxy-trans-stilbene), a member of the natural flavonoid family including various fruits and vegetables, has various physiological activities such as anti-inflammatory and antioxidant effects (Arai et al., 2000; Xia et al., 2017; Meng et al., 2021). Therefore, it is a common ingredient in healthy functional foods and known for its minimal adverse effects (Khan et al., 2013). Several previous studies have reported that resveratrol shows anticancer effects, although its molecular mechanism remains unclear (Ko et al., 2017; Lucas et al., 2018; Ren et al., 2021).

In this study, resveratrol as a GPER agonist was investigated and compared with G1 and G15 as negative control (Fig. 1). To elucidate whether GPER could play a role as a target on the chemotherapeutic effect of CRC, we investigated whether resveratrol showed an anticancer effect depending on GPER expression.

Figure 1. Structural formulas of compounds used in the experiments.

Cell lines and culture

Human colorectal cancer RKO cells (CRL-2577, ATCC, Manassas, VA, USA) and WiDr cells (CCL-218, ATCC) were grown in an Eagle’s minimum essential medium (GenDEPOT, Barker, TX, USA) containing 10% fetal bovine serum (GW Vitek, Seoul, Korea) and 1% penicillin/streptomycin (GenDEPOT) at 37°C in a humidified 5% CO2 incubator.

Organoid culture

This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Korea Cancer Center Hospital (approval no. KIRAMS-2017-07-001). Informed consent was not required for this study. Human CRC patient-derived organoids (30T and 33T) were obtained from the KIRAMS. The culture medium contained 1×B27 (Gibco, Grand Island, NY, USA), 1.25 mM N-acetyl cysteine (United States Pharmacopeia, Rockville, MD, USA), 50 ng/mL human epidermal growth factor (BioVision Inc., Milpitas, CA, USA), 50 ng/mL human Noggin (Peprotech, Rocky Hill, NJ, USA), 10 nM gastrin (Sigma-Aldrich, Merck KGaA, St. Louis, MO, USA), 500 nM A83-01 (BioVision Inc.), and 100 mg/mL primocin (InvivoGen, San Diego, CA, USA). For the first 2-3 d, organoids were cultivated in a culture medium also containing 10 M Y-27632 to prevent anoikis.

Cell viability assay

The viability of RKO and WiDr cells was evaluated via MTT assay. The cells (3-5×103 cells/well) were seeded into 96-well plates before being incubated for 24 h. Resveratrol (CAS No. 501-36-0, Aladdin, Shanghai, China), G1 (Cayman, MI, USA), and G15 (Cayman) were dissolved in 0.2 % dimethyl sulfoxide (DMSO) (Sigma-Aldrich). The cells were then treated with resveratrol (25, 50, 60, and 70 μM), G1 (0.5, 0.75, 1, 1.25 μM), and G15 (0.34, 0.67, 1.35, 2.7 μM) for 48 h. A 10 μL solution of MTT (5 mg/mL, BioVision, Inc.) was applied to each well before incubating for 3 h at 37°C. After removing the medium, 100 μL of DMSO (Sigma-Aldrich) was added to each well before being incubated for 30 min.

The viability of organoids was assessed by MTS assay according to a previous study (Park et al., 2020). Suspended organoids (5,000 cells) in the gel were then divided into a 96-well plate including 10 µL/well of matrigel, before 100 µL of culture medium was added. After 24 h, organoids were treated with resveratrol (25 and 50 μM in 0.2% DMSO) for 7 d. MTS solution (20 µL in each well, G3580, Promega, Madison, WI, USA) was added to each well before being incubated at 37°C for 3 h.

Subsequently, 560 nm (MTT assay) or 490 nm (MTS assay) of absorbance was measured using a microplate reader (Infinite M200 PRO, TECAN, Männedorf, Switzerland). All assays were repeated thrice. Additionally, for all assays, data are presented as mean ± standard deviation (SD) (n=6).

Clonogenic assay

RKO and WiDr cells were both seeded in 6-well plates at densities of 100 cells/well (control cells) and 500 cells/well (resveratrol- or G1-treated cells) (n=6 per group), respectively. After treatment with resveratrol (25 μM) and G1 (0.5 μM), cells were incubated for 10 d to form colonies of 50 cells or more. Subsequently, 0.25% crystal violet (Sigma-Aldrich) in 25% methanol (DUKSAN, Seoul, Korea) was applied to stain the colonies. The plating efficiency (PE) was used to standardize the variation in the number of seeded cells. The survival fraction (SF) was calculated using each of the following equations:

PE=number of colonies observednumber of cells plated
SF=number of colonies counted after treatmentnumber of cells plated×(PE)


The animal study was approved by the Duksung Women’s University Institutional Animal Care and Use Committee (2022-001-012) according to the regulations for the care and use of laboratory animals. BALB/c-Foxn1nu/Arc (Balb/c-nude) mice (male, 5-weeks old) were purchased from JA BIO (Suwon, Korea). The mice were acclimated to the animal laboratory environment for a week, under the following conditions: 28°C, 50% humidity, a 12 h light/dark cycle, and unlimited food and water.

Tumor growth curve

To establish the CRC cells-derived xenograft models, 100 µL/mice of RKO (5×107 cells/mL with 10% matrigel) and WiDr (3×107 cells/mL with 10% matrigel) cells were both subcutaneously transplanted into Balb/c-nude. Once the volume of tumors reached approximately 50 mm3, the mice were randomly divided into two groups (control and resveratrol-treated groups, n=5/group). Resveratrol (200 mg/kg) was intraperitoneally injected 3 d per week for four weeks, as previously described (Chávez et al., 2008; Ji et al., 2015). Tumor size was also measured thrice per week using calipers, with tumor volume being calculated using the following equation:

Tumor volume (mm3)=(Longest length)×(Shortest length)22

Western blot analysis

CRC cells (RKO and WiDr), patient-derived organoids (30T and 33T), and tumor tissues were all lysed with radioimmunoprecipitation assay (RIPA) buffer (GenDEPOT) containing protease (P3100, GenDEPOT) and phosphatase (Roche, Basel, Switzerland) inhibitors. Proteins (20 g) were separated by 12% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Sigma-Aldrich). Primary antibodies were incubated on the membranes overnight at 4°C. Antibodies included extracellular signal-regulated kinase (ERK, Invitrogen, Carlsbad, CA, USA, 1:1,000), p-ERK (Invitrogen, 1:1,000), Akt (Santa Cruz Biotechnology, Dallas, TX, USA, 1:1,000), p-Akt, poly (ADP-ribose) polymerase (PARP, Cell signaling technology, 1:1,000), Bax (BD Biosciences, Franklin Lakes, USA, 1:1,000), GPER (ab137479, Abcam, Eugene, OR, USA, 1:1,000), and GAPDH (Sigma-Aldrich, 1:5,000). Subsequently, the washed membranes were incubated with secondary anti-mouse and anti-rabbit antibodies (1:3,000) for 3 h at 25°C. Proteins were then visualized using a chemiluminescent solution (Thermo Fisher Scientific, Waltham, MA, USA), and images were obtained using a Chemi-doc (FluorChem E system, San Jose, CA, USA).

Statistical analysis

All data were evaluated by Student’s t-test or analysis of variance (ANOVA) using GraphPad Prism 7 (GraphPad Software Inc., CA, USA). Dunnett’s test and Sidak’s test were also used for multiple comparisons via the one-way and two-way ANOVA post hoc analyses, respectively. Data are presented as the mean ± SD, with statistical significance being set at p<0.05.


Comparison of GPER expression levels in CRC cell lines and patient-derived organoids

To investigate whether the effect of resveratrol was affected by GPER expression level, the expression levels of GPER were compared among cell lines and patient-derived organoids. As shown in Fig. 2A, RKO was selected as a CRC cell line with high GPER expression, whereas WiDr was selected as a CRC cell line with low expression. Additionally, among the eight patient-derived CRC organoids, 30T was selected as an organoid with high GPER expression, whereas 33T was selected as an organoid with low GPER expression (Fig. 2B).

Figure 2. Protein expression level of GPER in (A) CRC cells and (B) human CRC organoids. GPER protein levels were examined in (A) three types of CRC cells and (B) each CRC organoids derived from eight patients.

Anticancer effect of resveratrol is more sensitive in RKO cells than in WiDr cells

Resveratrol inhibited the cell viability more sensitively in RKO cells than in WiDr cells (Fig. 3A). The IC50 values of resveratrol were 58.7 μM for RKO cells and 181.9 μM for WiDr cells. G1 as a GPER agonist also showed higher cytotoxicity in RKO cells than in WiDr cells, whereas G15 as a GPER antagonist showed no cytotoxicity in either cells. In addition, resveratrol significantly suppressed cell proliferation in RKO cells than in WiDr cells (Fig. 3B). To investigate the mechanism of resveratrol, several protein levels were compared in these cells treated with resveratrol. As shown in Fig. 3C, the expression levels of p-ERK, Bax, and cleaved-PARP proteins were increased in RKO cells but remained unchanged in WiDr cells. However, resveratrol decreased the expression level of p-Akt only in WiDr cells.

Figure 3. Anticancer effect of resveratrol in CRC cells. (A) Inhibition of cell viability by resveratrol (Res). Res, G1, and G15 were treated in RKO and WiDr cells for 48 h, while cell viability was measured by MTT assay as described in the Materials and Methods. Data represent the mean ± SD (n=6). *p<0.05; ***p<0.001 (vs. control, one-way ANOVA with Dunnett’s post hoc test). (B) Suppression of cell proliferation by Res. As the clonogenic assay, the survival fraction (SF) was calculated. Data represent the mean ± SD (n=3). *p<0.05; **p<0.001; ***p<0.0001 (One-way ANOVA with Dunnett’s post hoc test). (C) Change in protein expression levels by Res. Cells were treated with Res (100 μM) and G1 (2 μM) for 3 h. All data represent the mean ± SD (n=3). *p<0.05, **p<0.0001 (Two-way ANOVA with Sidak’s post hoc test).

Inhibition of tumor growth by resveratrol in CRC cell-derived xenograft models

Resveratrol significantly inhibited tumor growth in the RKO cell-derived xenograft model but not in the WiDr cell-derived xenograft model (Fig. 4A). No change was observed in the body weight for these models (Fig. 4B). However, according to the ethical guidelines for experimental animals, a tumor volume exceeding 2,000 mm3 was considered as an indicator of death; therefore, survival rate was measured (Fig. 4C). The final survival rate of the control group was 16.7%, whereas that of resveratrol-treated group was 50%. Furthermore, resveratrol increased p-ERK, Bax, and cleaved-PARP protein expression only in the tumor tissues of the RKO cell-derived xenograft model but not in those of the WiDr cell-derived xenograft model (Fig. 4D).

Figure 4. Suppression of tumor growth by resveratrol in xenograft models. Res (200 mg/kg, i.p., 3 times/week) was treated into RKO cells- and WiDr cells-derived xenograft models. (A) Tumor growth delay. (B) Change in body weight in xenograft models. (C) Survival rate of Res in RKO cells-derived xenograft model. All data represent the mean ± SD (n=5). *p<0.05 (Two-way ANOVA with Sidak’s post hoc test). (D) Protein expression levels of tumor tissues derived from xenograft models. Data represent the mean ± SD (n=6). *p<0.05, **p<0.0001 (Two-way ANOVA with Sidak’s post hoc test).

Chemotherapeutic effect of resveratrol in CRC patient-derived organoids with high GPER expression

The chemotherapeutic effect of resveratrol was further investigated in two CRC patient-derived organoids, as shown in Fig. 2B. Resveratrol significantly inhibited cell proliferation only in 30 T with high-GEPR expression but not in 33 T with low GPER expression (Fig. 5A). The morphology of two organoids was shown in Fig. 5B. The expression levels of p-ERK, Bax, and cleaved-PARP proteins were increased by resveratrol via GPER in organoids (Fig. 5C). However, resveratrol decreased the expression level of p-Akt in 33T as in WiDr cells.

Figure 5. Anticancer effect of resveratrol in CRC patient-derived organoids. (A) Suppression of organoid viability. Res was treated into 30T and 33T organoids for 7 d, and viability was measured by MTS assay as described in the Materials and Methods. Data represent the mean ± SD (n=6). ***p<0.001 (vs. control, one-way ANOVA with Dunnett’s post hoc test). (B) Morphology of CRC patient-derived organoids (30T and 33T) treated with Res. (C) Change in protein expression levels by Res.

Our results suggested that resveratrol stimulated an anticancer effect via GPER activation, which is a target for the therapeutic strategy of CRC. To elucidate the anticancer effect of resveratrol via GPER, we compared them between two CRC cell lines and two xenograft models, depending on GPER expression level (Fig. 3, 4). Notably, our hypothesis was also demonstrated in CRC patient-derived organoids (Fig. 5), which have the patient’s physiological and genetic characteristics (Broutier et al., 2017; Kondo and Inoue, 2019; Kwon et al., 2021; Sakalem et al., 2021).

Resveratrol reportedly increases the expression of antioxidant enzymes (Xia et al., 2017) and regulates molecular signaling pathways such as AMPK, ROS, and Wnt (Vernousfaderani et al., 2021). Resveratrol also possesses anti-inflammatory and antioxidant activities, which can potentially serve as chemo-adjuvant (Arai et al., 2000; Xia et al., 2017; Meng et al., 2021). The cytotoxicity of resveratrol in WiDr cells expressed a low level of GPER, which may have been shown by these physiological activities (Fig. 3). As its mechanism, resveratrol inhibits CRC epithelial-to-mesenchymal metastasis through the expression of Snail/E-cadherin via the TGF-β1/Smads signaling pathway (Ji et al., 2015) and induces apoptosis by increasing reactive oxygen species through mitochondrial pathway (Fu et al., 2021). Our results demonstrated that resveratrol significantly delayed tumor growth, while inducing apoptosis through the ERK and Akt pathways in CRC. The ERK (Zhou et al., 2019), Bax (Bahadori et al., 2016), and PARP pathways (Cruz-Nova et al., 2018) have all been reported to induce apoptosis and inhibit cell proliferation.

The role of GPER in the progression of CRC has not yet been elucidated and thus remains a topic of debate. Steroid sulfatase activates the estrogen pathway via GPER activation and increased the proliferation of CRC (Gilligan et al., 2017). However, GPER activation increased ER stress in breast cancer MCF-7 cells (Vo et al., 2019) and blocked Wnt-induced-JUN upregulation in CRC H29 cells (Abancens et al., 2022), leading to apoptosis. Our results showed that resveratrol stimulated the anticancer effect on high GPER-expressed cancer cells. D’Arrigo et al. (2021) previously reported that resveratrol showed direct docking to GPER binding pocket. Our results also suggested that resveratrol induced the phosphorylation of ERK and increased Bax, while cleaving PARP via GPER in vitro and in vivo. This indicated that the activity of GPER-mediated signaling by resveratrol inhibited CRC progression (Fig. 6). In particular, the anticancer effect of resveratrol on CRC patient-derived organoids suggests its potential for clinical applications in CRC treatment.

Figure 6. Anticancer effect of resveratrol depending on GPER expression in CRC.

This research was supported by an NRF grant funded by MSIT (NRF-2021R1A2C2004535), the Priority Research Centers Program through NRF funded by the Ministry of Education (2016R1A6A1A03007648) (J.J.), and a grant of the KIRAMS funded by MSIT, the Republic of Korea (No. 50542-2022) (U.S.).


The authors have no conflicts of interest relevant to this study to disclose.

  1. Abancens, M., Harvey, B. J. and McBryan, J. (2022) GPER agonist G1 prevents Wnt-induced JUN upregulation in HT29 colorectal cancer cells. Int. J. Mol. Sci. 23, 12581.
    Pubmed KoreaMed CrossRef
  2. Arai, Y., Watanabe, S., Kimira, M., Shimoi, K., Mochizuki, R. and Kinae, N. (2000) Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J. Nutr. 130, 2243-2250.
    Pubmed CrossRef
  3. Bahadori, M., Baharara, J. and Amini, E. (2016) Anticancer properties of chrysin on colon cancer cells, in vitro and in vivo with modulation of caspase-3, −9, Bax and Sall4. Iran. J. Biotechnol. 14, 177-184.
    Pubmed KoreaMed CrossRef
  4. Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., Georgakopoulos, N., Koo, B. K., Dietmann, S., Davies, S. E., Praseedom, R. K., Lieshout, R., IJzermans, J. N. M., Wigmore, S. J., Saeb-Parsy, K., Garnett, M. J., van der Laan, L. J. and Huch, M. (2017) Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 23, 1424-1435.
    Pubmed KoreaMed CrossRef
  5. Chávez, E., Reyes-Gordillo, K., Segovia, J., Shibayama, M., Tsutsumi, V., Vergara, P., Moreno, M. G. and Muriel, P. (2008) Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J. Appl. Toxicol. 28, 35-43.
    Pubmed CrossRef
  6. Cruz-Nova, P., Schnoor, M., Correa-Basurto, J., Bello, M., Briseño-Diaz, P., Rojo-Domínguez, A., Ortiz-Mendoza, C. M., Guerrero-Aguirre, J., García-Vázquez, F. J., Hernández-Rivas, R., Thompson-Bonilla, M. D. R. and Vargas, M. (2018) The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo. BMC Cancer 18, 1056.
    Pubmed KoreaMed CrossRef
  7. D'Arrigo, G., Gianquinto, E., Rossetti, G., Cruciani, G., Lorenzetti, S. and Spyrakis, F. (2021) Binding of androgen- and estrogen-like flavonoids to their cognate (non)nuclear receptors: a comparison by computational prediction. Molecules 26, 1613.
    Pubmed KoreaMed CrossRef
  8. Di Leo, A., Messa, C., Cavallini, A. and Linsalata, M. (2001) Estrogens and colorectal cancer. Curr. Drug Targets Immune Endocr. Metabol. Disord. 1, 1-12.
    Pubmed CrossRef
  9. Fu, Y., Ye, Y., Zhu, G., Xu, Y., Sun, J., Wu, H., Feng, F., Wen, Z., Jiang, S., Li, Y. and Zhang, Q. (2021) Resveratrol induces human colorectal cancer cell apoptosis by activating the mitochondrial pathway via increasing reactive oxygen species. Mol. Med. Rep. 23, 170.
    Pubmed CrossRef
  10. Gilligan, L. C., Rahman, H. P., Hewitt, A. M., Sitch, A. J., Gondal, A., Arvaniti, A., Taylor, A. E., Read, M. L., Morton, D. G. and Foster, P. A. (2017) Estrogen activation by steroid sulfatase increases colorectal cancer proliferation via GPER. J. Clin. Endocrinol. Metab. 102, 4435-4447.
    Pubmed KoreaMed CrossRef
  11. Hsu, L. H., Chu, N. M., Lin, Y. F. and Kao, S. H. (2019) G-protein coupled estrogen receptor in breast cancer. Int. J. Mol. Sci. 20, 306.
    Pubmed KoreaMed CrossRef
  12. Ji, Q., Liu, X., Han, Z., Zhou, L., Sui, H., Yan, L., Jiang, H., Ren, J., Cai, J. and Li, Q. (2015) Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression. BMC Cancer 15, 97.
    Pubmed KoreaMed CrossRef
  13. Jung, J. (2019) Role of G protein-coupled estrogen receptor in cancer progression. Toxicol. Res. 35, 209-214.
    Pubmed KoreaMed CrossRef
  14. Khan, N., Syed, D. N., Ahmad, N. and Mukhtar, H. (2013) Fisetin: a dietary antioxidant for health promotion. Antioxid. Redox Signal. 19, 151-162.
    Pubmed KoreaMed CrossRef
  15. Khil, H., Kim, S. M., Hong, S., Gil, H. M., Cheon, E., Lee, D. H., Kim, Y. A. and Keum, N. (2021) Time trends of colorectal cancer incidence and associated lifestyle factors in South Korea. Sci. Rep. 11, 2413.
    Pubmed KoreaMed CrossRef
  16. Ko, J. H., Sethi, G., Um, J. Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., Bishayee, A. and Ahn, K. S. (2017) The role of resveratrol in cancer therapy. Int. J. Mol. Sci. 18, 2589.
    Pubmed KoreaMed CrossRef
  17. Kondo, J. and Inoue, M. (2019) Application of cancer organoid model for drug screening and personalized therapy. Cells 8, 470.
    Pubmed KoreaMed CrossRef
  18. Kwon, J., Oh, S., Park, M., Kong, J. S., Lee, S., Lee, H., Kim, Y., Kang, K. T., Shin, U. S. and Jung, J. (2021) Advanced xenograft model with cotransplantation of patient-derived organoids and endothelial colony-forming cells for precision medicine. J. Oncol. 2021, 9994535.
    Pubmed KoreaMed CrossRef
  19. Liu, Q., Chen, Z., Jiang, G., Zhou, Y., Yang, X., Huang, H., Liu, H., Du, J. and Wang, H. (2017) Epigenetic down regulation of G protein-coupled estrogen receptor (GPER) functions as a tumor suppressor in colorectal cancer. Mol. Cancer 16, 87.
    Pubmed KoreaMed CrossRef
  20. Lucas, J., Hsieh, T. C., Halicka, H. D., Darzynkiewicz, Z. and Wu, J. M. (2018) Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF-κB signaling. Int. J. Oncol. 53, 1469-1480.
    Pubmed KoreaMed CrossRef
  21. Luo, J. and Liu, D. (2020) Does GPER really function as a G protein-coupled estrogen receptor in vivo?. Front. Endocrinol. (Lausanne) 11, 148.
    Pubmed KoreaMed CrossRef
  22. Meng, T., Xiao, D., Muhammed, A., Deng, J., Chen, L. and He, J. (2021) Anti-inflammatory action and mechanisms of resveratrol. Molecules 26, 229.
    Pubmed KoreaMed CrossRef
  23. Park, M., Kwon, J., Shin, H. J., Moon, S. M., Kim, S. B., Shin, U. S., Han, Y. H. and Kim, Y. (2020) Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient-derived organoids. Int. J. Oncol. 57, 1307-1318.
    Pubmed KoreaMed CrossRef
  24. Qiu, Y. A., Xiong, J. and Yu, T. (2021) Role of G protein-coupled estrogen receptor in digestive system carcinomas: a minireview. Onco Targets Ther. 14, 2611-2622.
    Pubmed KoreaMed CrossRef
  25. Ren, B., Kwah, M. X., Liu, C., Ma, Z., Shanmugam, M. K., Ding, L., Xiang, X., Ho, P. C., Wang, L., Ong, P. S. and Goh, B. C. (2021) Resveratrol for cancer therapy: challenges and future perspectives. Cancer Lett. 515, 63-72.
    Pubmed CrossRef
  26. Sakalem, M. E., De Sibio, M. T., da Costa, F. A. D. S. and de Oliveira, M. (2021) Historical evolution of spheroids and organoids, and possibilities of use in life sciences and medicine. Biotechnol. J. 16, e2000463.
    Pubmed CrossRef
  27. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209-249.
    Pubmed CrossRef
  28. Vernousfaderani, E. K., Akhtari, N., Rezaei, S., Rezaee, Y., Shiranirad, S., Mashhadi, M., Hashemi, A., Khankandi, H. P. and Behzad, S. (2021) Resveratrol and colorectal cancer: a molecular approach to clinical researches. Curr. Top. Med. Chem. 21, 2634-2646.
    Pubmed CrossRef
  29. Vo, D. H., Hartig, R., Weinert, S., Haybaeck, J. and Nass, N. (2019) G-protein-coupled estrogen receptor (GPER)-specific agonist G1 induces ER stress leading to cell death in MCF-7 cells. Biomolecules 9, 503.
    Pubmed KoreaMed CrossRef
  30. Xia, N., Daiber, A., Förstermann, U. and Li, H. (2017) Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 174, 1633-1646.
    Pubmed KoreaMed CrossRef
  31. Zhou, G., Yang, J. and Song, P. (2019) Correlation of ERK/MAPK signaling pathway with proliferation and apoptosis of colon cancer cells. Oncol. Lett. 17, 2266-2270.
    Pubmed KoreaMed CrossRef

This Article

Cited By Articles

Funding Information

Social Network Service